Open AccessIncretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
Author(s) -
Iuliia V. Silko,
Tatiana Vasil'evikonova,
Marina V. Shestakova
Publication year - 2016
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/omet201623-6
Subject(s) - incretin , medicine , diabetes mellitus , insulin , autoimmune diabetes , endocrinology , glucagon like peptide 1 , type 2 diabetes , glucagon like peptide 1 receptor , agonist , pathogenesis , type 1 diabetes , receptor
Recently, the bihormonal theory of the autoimmune diabetes development is discussed in the world literature. The abnormal suppression of glucagon and reduced incretin response are considered in the development and progression of type 1 diabetes mellitus in addition to insulin deficiency. Animal studies demonstrate a GLP-1 – role in beta cell-proliferation and decrease in apoptosis. The information concerning the functioning of the incretin system in patients with type 1 diabetes and LADA is systematized in the present review. We also discuss the studies of the use of GLP-1 agonists in patients with autoimmune diabetes.